This book proposes a concrete path to bring an end to pandemics and achieve a world without infectious diseases, suggesting an escape from the long history of infectious diseases that have brought misery and confusion to humanity. The book presents an Mikawa-Kase-AQIP model to illuminate the generation of infection units originating from the lungs, where viral proliferation occurs. It further elucidates the theoretical distribution of viruses entrapped within aerosol particles. It is entirely possible to avoid infection using today's science and technology, if we all understand, share, and implement an air ventilation approach which will stop viruses from entering the body. The challenge to eradicate future pandemics must be confronted now. The aim in this book is to present the answer.
See more
Current price
€76.94
Original price
€80.99
Save 5%
Delivery/Collection within 10-20 working days
Product Details
Dimensions: 148 x 212mm
Publication Date: 17 Apr 2024
Publisher: Cambridge Scholars Publishing
Publication City/Country: United Kingdom
Language: English
ISBN13: 9781036403072
About Hiroshi KaseYoshikazu G. Mikawa
Hiroshi Kase PhD joined Kyowa Hakko Kogyo Co. Ltd. (Japan) in 1966 and served as researcher as Director of the Pharmaceutical Research Institute and as Global Project Leader. As a representative accomplishment he was involved in the discovery and development of adenosine A2A antagonist KW-6002 (istradefylline) for a new Parkinson's Disease drug with a novel action mechanism leading to success in its launch in Japan and the United States. He is the author and editor of Adenosine Receptor and Parkinson's Disease (2000).Yoshikazu G. Mikawa MD PhD joined Dr Sydney Brenner's Molecular Genetics Unit in Cambridge UK in 1989 and collaborated in the USA until 2005. His work propelled DNA technologies particularly in the next-generation sequencing. He developed a bacteriophage lambda peptide display system and genetically modified bacteria for ligand-receptor binding analysis. He was Principal Scientific Officer at Population Genetics Technologies Ltd UK (2005-2013). He co-founded Nemesis Bioscience Ltd (UK) in 2014 focusing on cutting-edge technologies addressing antimicrobial resistance.